GlassScriptPhysician profile
Hiral Thakrar
NPI 1487033098
$19,202.04
in general payments reported to CMS, 2019-2025
31 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $71.78 · 2021: $573 · 2022: $603 · 2023: $596 · 2024: $1,403 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,990 · Travel and Lodging: $899 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,571.00 |
| Food and Beverage | $4,989.62 |
| Travel and Lodging | $899.14 |
| Education | $110.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,747.82 | 2024-2025 | Ebglyss |
| Eli Lilly and Company | $5,381.00 | 2025 | Ebglyss |
| Genzyme Corporation | $2,148.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,100.34 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $891.07 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $556.43 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $523.76 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $521.99 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $395.12 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $298.36 | 2021-2025 | Ruconest, Joenja |
| Genentech USA, INC. | $182.76 | 2021-2025 | Xolair |
| Grifols USA, LLC | $182.68 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $167.93 | 2019-2025 | |
| Kaleo, INC. | $161.92 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $131.62 | 2022-2025 | Orladeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $126.15 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $104.21 | 2025 | Yupelri |
| Genentech, INC. | $92.90 | 2025 | Xolair |
| Pfizer INC. | $81.73 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $49.57 | 2025 | Neffy |
| Blueprint Medicines Corporation | $48.94 | 2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.48 | 2019-2022 | |
| Gc Biopharma USA, INC. | $45.69 | 2025 | Alyglo |
| Teva Pharmaceuticals USA, INC. | $45.02 | 2021-2022 | |
| Octapharma USA, INC. | $37.90 | 2024 | Panzyga |
| Abbvie INC. | $28.79 | 2023 | Rinvoq |
| Alk-Abello, INC | $25.36 | 2020 | |
| Incyte Corporation | $23.33 | 2025 | Opzelura |
| Mylan Specialty L.P. | $19.15 | 2024 | Yupelri |
| Circassia INC. | $17.44 | 2019 | |
| Ionis Pharmaceuticals, INC. | $17.27 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiral Thakrar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.